Journal of Oncology Pharmacy Practice最新文献

{"title":"Predictive risk factors associated with cancer therapy-related cardiac dysfunction: A retrospective cohort study.","authors":"Bruna Brito Machado, Andreia Biolo, Fernando Pivatto Júnior, Alana de Quadros Schroeder, Marco Aurélio Lumertz Saffi","doi":"10.1177/10781552251358183","DOIUrl":"https://doi.org/10.1177/10781552251358183","url":null,"abstract":"<p><p>IntroductionThe increasing cardiovascular events in cancer patients underscore the importance of identifying preexisting risk factors as predictors of heart disease outcomes. This study aimed to assess the predictive risk factors associated with cancer therapy-related cardiac dysfunction (CTRCD) in female patients with breast cancer undergoing treatment with anthracyclines and/or anti-HER-2 therapies.MethodsA cohort study was conducted at a university hospital outpatient clinic from 2019 to 2024. CTRCD was defined according to the European Society of Cardiology criteria as an absolute LVEF reduction of >10 percentage points to <50% during treatment.ResultsA total of 161 female patients were analyzed (mean age: 51.2 ± 11.6 years), with most being white/Caucasian (83.8%). The most prevalent cardiovascular risk factors were hypertension (47.2%), obesity (31.7%), smoking (31.0%), dyslipidemia (14.3%), and type 2 diabetes mellitus (12.4%). CTRCD occurred in 18 patients (11.1%), with a markedly higher prevalence (27.3%) in those with four or more cardiovascular risk factors. The median time (IQR) from the initiation of chemotherapy to CTRCD was 395 (248-674) days. Multivariable analysis identified the Charlson comorbidity index (HR 1.2; 95% CI: 1.0-1.4), chemotherapy duration (HR 1.0; 95%CI: 1.0-1.0) and LVEF before (HR 0.8; 95%CI: 0.7-0.9) and after chemotherapy (HR 0.8; 95%CI: 0.8-0.9) as independent factors for CTRCD. Breast cancer patients had a 17.7% risk of developing CTRCD within the first two years of antineoplastic treatment.ConclusionHypertension, obesity, and smoking were the most prevalent cardiovascular risk factors. Independent predictors of CTRCD included the Charlson comorbidity index, chemotherapy duration, and LVEF before and after treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358183"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laryngopharyngeal dysesthesia as a possible clinical manifestation of a cytokine release reaction due to oxaliplatin.","authors":"Maria Cruz Torres Gorriz, Julián Borras Cuartero, Paula Viedma Ayllón, Jorge Molina Saera, Ernesto Enrique","doi":"10.1177/10781552251358672","DOIUrl":"https://doi.org/10.1177/10781552251358672","url":null,"abstract":"<p><p>IntroductionLaryngopharyngeal dysesthesia is considered an acute peripheral neuropathy secondary to oxaliplatin neurotoxicity.Case reportWe report a case of laryngopharyngeal dysesthesia that developed in a patient with colon adenocarcinoma after receiving her third cycle of oxaliplatin.Management & outcomeShe was treated with antihistamines, steroids, oxygen, and adrenaline and referred to the allergy department for investigation of a hypersensitivity reaction to the drug. Skin tests and tryptase extracted after the acute episode ruled out this possibility. However, the patient presented a slight elevation of interleukin 6, commonly observed in cytokine release reactions. The patient continued her oxaliplatin treatment with cautious administration and under the supervision of the allergist.DiscussionLaryngopharyngeal dysesthesia is part of oxaliplatin neurotoxicity and does not require discontinuation of the drug. However, in patients with severe laryngopharyngeal dysesthesia symptoms, it would be advisable to perform a differential diagnosis with hypersensitivity reactions and cytokine release reactions, whose management differs from neurotoxic reactions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358672"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Frequency of adverse drug reactions in cancer patients: A study at the oncology department of a university hospital.","authors":"Zeynep Erdogmus Ozgen, Barıs Asana, Muhammed Mansur Ozgen","doi":"10.1177/10781552251358171","DOIUrl":"https://doi.org/10.1177/10781552251358171","url":null,"abstract":"<p><p>ObjectivesWe aimed to investigate the adverse drug reactions (ADRs) observed in cancer patients, the drugs causing ADRs, ADRs reporting rate, common adverse effects, drug interactions, and the drugs used to manage these adverse effects.MethodsA questionnaire about pharmacovigilance, the most common ADRs and side effects observed in oncology patients, the frequency of these ADRs, the drugs causing them, and drug interactions was administered to the volunteers in our study.ResultsAlthough 66 out of the 90 nurses who participated in the study reported having previously encountered an ADR, only 39 of them actually reported it. ADRs were most frequently seen once a year or more and 56% of the ADRs were life-threatening, 21% medically important and 23% resulted in hospitalization. The pharmacological groups with the most ADR reports were; Taxanes, Platinum compounds, Monoclonal antibody (Mabs), Antimetabolites, Alkylating agents, Topoisomerase inhibitors and alkaloids respectively. ADRs were specifically related to Paclitaxel, Cisplatin and Rituximab. The most common adverse effects included; redness, itching, dyspnea and tachycardia. Antihistamines and corticosteroids were most commonly used in treatment of ADRs. The drugs that interacted most with antineoplastics were antibiotics, anticonvulsants and antihypertensives.ConclusionAlthough the incidence of ADRs in cancer patients is high, the reporting rate is relatively low. ADRs associated with antineoplastic drugs are serious reactions. Identifying which drugs cause the most ADRs is crucial for prevention, monitoring, and treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358171"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive management strategies for amivantamab-induced toxicities and review of the literature.","authors":"Furkan Ceylan, Gamze Sonmez, Ates Kutay Tenekeci, Ahmet Arda Unal, Mehmet Ali Nahit Sendur","doi":"10.1177/10781552251358871","DOIUrl":"https://doi.org/10.1177/10781552251358871","url":null,"abstract":"<p><p>BackgroundLung cancer is a leading cause of cancer-related deaths, with Non-Small Cell Lung Cancer (NSCLC) comprising 85-90% of cases, most commonly adenocarcinoma. Key mutations include EGFR Exon 19 deletions and Exon 21 L858R. While third-generation TKIs like osimertinib, lazertinib, and aumolertinib are effective, resistance often arises. Amivantamab, a bispecific monoclonal antibody targeting EGFR and c-MET, shows promise, particularly against EGFR Exon 20 insertions.ObjectiveTo provide a comprehensive evaluation of the adverse effects associated with amivantamab in EGFR-mutant NSCLC, including their underlying pathophysiological mechanisms and evidence-based management strategies. In addition, this review aims to contextualize the clinical relevance of amivantamab by briefly outlining the therapeutic evolution of EGFR-targeted treatments, highlighting the rationale for its development, and current positioning in treatment paradigms.MethodsA comprehensive review of clinical trials, including CHRYSALIS, PAPILLON, MARIPOSA, and PALOMA-III, was conducted to assess the safety and efficacy of amivantamab. Practical and early insights into managing adverse effects of amivantamab are critical to better adherence and quality of life.ResultsAdverse effects were observed in most of the patients treated with amivantamab. Common side effects included cutaneous toxicities, diarrhea, infusion-related reactions (IRRs), vascular thrombosis and pneumonitis. The most frequent cutaneous side effects were rash, paronychia, pruritis, and stomatitis. Diarrhea occurred in patients primarily due to EGFR inhibition. IRRs were predominantly mild to moderate, occurring mainly during the first cycle. Thrombosis was a notable adverse effect observed, even in patients receiving anticoagulant prophylaxis. Pneumonitis was less common but severe.ManagementAdverse effects of amivantamab are managed based on severity. Cutaneous toxicities are treated with antibiotics, topical steroids, and dose adjustments. Diarrhea is managed with hydration, loperamide, and dose interruption. Infusion-related reactions (IRRs) are treated symptomatically, with epinephrine in severe cases. Anticoagulants are used for deep vein thrombosis or thromboembolism, and fibrinolytics or thrombectomy may be considered. Pneumonitis is managed by discontinuing amivantamab and using glucocorticoids.ConclusionsAmivantamab is effective for EGFR mutant NSCLC but can cause adverse effects. Understanding these effects and implementing management strategies can optimize outcomes, maintaining treatment efficacy.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358871"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637333","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cross-cultural adaptation to Brazilian Portuguese of the Indication for Common Toxicity Criteria Grading of Peripheral Neuropathy Questionnaire.","authors":"Leonardo Teodoro de Farias, Pryscila Rodrigues Moreira, Aline Dos Santos Iwasse, Luana Clara de Souza, Raíra Macário Silvério, Lunara Teles Silva, Tatyana Xavier Almeida Matteucci Ferreira, Renato Sampaio Tavares, Ana Carolina Figueiredo Modesto","doi":"10.1177/10781552251358347","DOIUrl":"https://doi.org/10.1177/10781552251358347","url":null,"abstract":"<p><p>BackgroundMultiple myeloma (MM) is a common hematological malignancy, and chemotherapy-induced peripheral neuropathy (CIPN) is one of its most significant adverse drug reactions. While CIPN can be managed through dose adjustments or treatment discontinuation, its assessment relies on patient-reported symptoms. The need for validated tools to accurately assess CIPN and support clinical decisions is critical to improving patient outcomes and ensuring more effective management strategies.AimTo perform the cross-cultural adaptation of the Indication for Common Toxicity Criteria Grading of Peripheral Neuropathy Questionnaire (ICPNQ) to Brazilian Portuguese.MethodThe cross-cultural adaptation process was conducted in five stages: (a) translation, (b) synthesis of translations, (c) submission of the translated version to a panel of experts, (d) pre-testing with the target population, and (e) back-translation into the original language.ResultsThe translation team included a specialist in onco-hematology, and the adapted version of the ICPNQ was evaluated by 20 healthcare professionals (nurses, pharmacists, and physicians) with an average of 9.5 years of experience in onco-hematology. The Content Validity Index (CVI) of the overall instrument was 0.98, while the CVIs for presentation and clarity were 0.98, and 0.97 for applicability. A pilot test was performed with 22 patients with MM in a specialized outpatient clinic for onco-hematological diseases in a university hospital. The patients were predominantly male (54.55%), over 65 years (59.09%), and using at least one neurotoxic drug (81.82<b>%).</b> Back-translation confirmed the semantic and cultural equivalence of the instrument's items.ConclusionThe Brazilian Portuguese version of the ICPNQ demonstrates semantic, idiomatic, cultural, and conceptual equivalence, suitable for application in the Brazilian context.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358347"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to Audit on Oral Systemic Anti-Cancer Therapies (SACT) Adherence Using the Morisky Medication Adherence Scale (MMAS): Implications for Pharmacy Counselling.","authors":"","doi":"10.1177/10781552251347796","DOIUrl":"https://doi.org/10.1177/10781552251347796","url":null,"abstract":"","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251347796"},"PeriodicalIF":1.0,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment duration of immune checkpoint inhibitors and overall survival in U.S. veterans with Cancer.","authors":"Sanya Z Hassan, Marshall J Tague, Mark A Klein, Brian C Lund","doi":"10.1177/10781552251357811","DOIUrl":"https://doi.org/10.1177/10781552251357811","url":null,"abstract":"<p><p>BackgroundOptimal treatment duration for immune checkpoint inhibitors (ICI) remains a clinical debate. The objective of this study was to contrast mortality rates between 2-year fixed versus indefinite treatment duration among patients initiating ICIs across a variety cancer types.MethodsThis retrospective observational study used national administrative data from the Veterans Health Administration to select patients who initiated an ICI between January 1, 2014, and December 31, 2020. ICI treatment duration was categorized as either fixed (2 years; 700-760 days) or indefinite (>760 days). A multivariate Cox proportional hazards regression model was used to examine the impact of duration on overall mortality.ResultsOf 1357 patients who received ICI treatment for at least 2 years, the probability of survival after 1 year was significantly lower in the fixed duration group (78.9%) compared to the indefinite duration group (87.6%; χ² = 12.6; df = 1; p < 0.001). At 2 years follow-up overall survival was not significantly different between groups (70.9% fixed vs. 76.5% indefinite; χ² = 3.5; df = 1; p = 0.061). In a multivariable Cox proportional hazards regression model, the adjusted HR for death for fixed versus indefinite duration groups was 1.22 (95% CI: 0.96-1.54), which did not reach statistical significance.ConclusionWhile failing to demonstrate a statistically significant difference, these findings suggest the potential for a clinically meaningful difference in mortality risk between fixed versus indefinite duration ICI treatment. These findings support the need for further research to determine the optimal duration for ICI treatment, and highlight weighing risks of mortality, immune-related adverse events, and financial cost.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251357811"},"PeriodicalIF":1.0,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144608619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mosunetuzumab-associated fatal HHV-6 encephalitis in a patient with follicular lymphoma.","authors":"Victor M Samperio, Moza Hamoud, Constantin A Dasanu","doi":"10.1177/10781552251355433","DOIUrl":"https://doi.org/10.1177/10781552251355433","url":null,"abstract":"<p><p>IntroductionMosunetuzumab is a CD3×CD20 bispecific antibody approved for relapsed/refractory follicular lymphoma. Although it was shown to achieve high response rates and durable remissions, immunosuppression with its use can be significant. Immune effector cell-associated neurotoxicity syndrome (ICANS) has been described with bispecific T-cell engager (BiTE) therapies, but human herpesvirus-6 (HHV-6) encephalitis has not been previously reported.CaseWe describe a 76-year-old woman with grade 3A follicular lymphoma treated with mosunetuzumab for twelve weeks. Ten days after the 4th cycle, she was admitted to the hospital with gradual onset of confusion and generalized weakness. Magnetic resonance imaging (MRI) showed bilateral mesial temporal T2/FLAIR hyperintensities. Cerebrospinal fluid (CSF) polymerase chain reaction (PCR) testing revealed HHV-6 infection.Management and outcomeICANS was initially suspected, and dexamethasone 10 mg IV daily was started. Following positive PCR testing for HHV-6, IV ganciclovir was commenced. Despite aggressive antiviral treatment, the patient's condition deteriorated and she died on hospital day 12.Discussion/conclusionSymptomatic HHV-6 reactivation has been recorded in the setting of allogeneic stem cell transplant and chimeric antigen receptor (CAR) T-cell therapy. This is the first instance of HHV-6 encephalitis associated with mosunetuzumab. The case underscores the importance of early CSF analysis and neuroimaging in patients with encephalopathy receiving T-cell-engaging therapies.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251355433"},"PeriodicalIF":1.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overcome Daratumumab' severe reaction with desensitization in relapsed multiple myeloma.","authors":"Trang L Nguyen, Truc Phan, Mai T Vu, Kn Vy Huynh, Yi Hyeon Gyu, Tuan D Nguyen, Lan Q Phan, Tuan D Nguyen, Dinh V Nguyen","doi":"10.1177/10781552251356918","DOIUrl":"https://doi.org/10.1177/10781552251356918","url":null,"abstract":"<p><p>IntroductionDaratumumab, a monoclonal antibody that specifically targets the myeloma cells' CD38 antigen, is promisingly used in both monotherapy and combination therapy for relapsed patients with multiple myeloma. However, this approach had a significant challenge due to the high rate of infusion-related reaction in the first dosage (up to 38%) despite strict instructions on infusion rate and dilution volume. This study describes a patient who overcame severe infusion reaction after the first dosage by desensitization.Case reportA 60-year-old man with multiple myeloma was relapsed with multiple bone damage and elevated immunoglobulin D lambda after VTD (bortezomid, thalidomide, dexamethasone) regimen completion. After 60 min of initial Daratumumab dose with sufficient pre-medication, the patient manifested suspected grade 3 infustion reaction and was transported to the intensive care unit.Management and outcomeDaratumumab was immediately terminated; <b>adrenaline,</b> methylprednisolone, and diphenhydramine were started. Another regimen was performed. However, due to substantial progression of symptoms, a re-introduction of daratumumab was considered. Daratumumab prick and intradermal skin test was performed with negative result. Desensitization were sucessfull with the number of bags and steps gradually lowered with no adverse events observed. After three cycles, the patient achieved VGPR (Very Good Partial Response) without any symptomatic spinal cord compression.ConclusionDesensitization is a promising solution to overcome daratumumab's severe infusion reaction, opening the new approach for clinicians. To ensure success, it is important to have a multidisciplinary team with experienced allergist, hematologist, Intensive Care Init (ICU) team and oncology pharmacist to create a safe environment for desensitization.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251356918"},"PeriodicalIF":1.0,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2-targeted agents and interstitial lung disease: A real-world pharmacovigilance analysis using FAERS data.","authors":"Huahua Zhang, Yandong Zhang, Xiaoying Wang, Jiangfeng Wang","doi":"10.1177/10781552251356906","DOIUrl":"https://doi.org/10.1177/10781552251356906","url":null,"abstract":"<p><p>IntroductionThere has been a growing concern regarding the interstitial lung disease (ILD) associated with HER2-targeted agents. This study aimed to elucidate the risk and characteristics of ILD associated with anti-HER2 agents using the FDA Adverse Event Reporting System (FAERS).MethodsData from 2004 Q1 to 2024 Q2 were extracted from the FAERS. The significant association between HER2-targeted agents and ILD was evaluated using the reporting odds ratio (ROR). Risk factors for mortality and time-to-onset were also assessed.ResultsA total of 2262 cases of HER2-targeted agents-associated ILD were identified. Positive signals were detected in trastuzumab deruxtecan (T-Dxd) (ROR = 31.28, 95% confidence interval [CI] 29.22-33.48), trastuzumab emtansine (T-DM1) (ROR = 6.27, 95% CI 5.38-7.32), pertuzumab (ROR = 6.08, 95% CI 5.36-6.89), trastuzumab (ROR = 4.02, 95% CI 3.73-4.33), tucatinib (ROR = 1.84, 95% CI 1.25-2.71), and lapatinib (ROR = 1.37, 95% CI 1.12-1.68). However, only two cases of ILD were associated with neratinib. The overall median time-to-onset was 75.5 days (interquartile range: 27.0-163.0). Logistic regression analysis revealed that elderly patients, treatment with T-Dxd, and treatment for non-breast cancer were significant risk factors for fatal outcomes related to ILD associated with HER2-targeted agents.ConclusionThis study suggests a significant association between the ILD and HER2-targeted agents, including T-Dxd, T-DM1, pertuzumab, trastuzumab, tucatinib, and lapatinib.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251356906"},"PeriodicalIF":1.0,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}